‘Barbarism:’ AOC Unleashes Fury On US Healthcare System As People Are ‘Choosing Between Medicine And Rent’
America has one of the highest healthcare costs in the world, with healthcare spending hitting $4.5 trillion in 2022.
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Pfizer’s Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE: SHAK)
Cigna Drops Humana Merger, Opts For $10 Billion Buyback Strategy
In a recent development in the health insurance sector, Cigna Corporation (NYSE: CI) has withdrawn from its proposed merger with Humana Inc. (NYSE:
Humana, Comerica, Cleveland-Cliffs, And More: CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Shannon Saccocia of Boston Private named iShares U.S.
Cisco, Burlington Stores, Broadcom And More On CNBC’s ‘Final Trades’
It has been "a really tough year" for the healthcare sector.
That's according to Shannon Saccocia of Boston Private, who appeared on CNBC’s "Halftime Report Final Trades."
Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups
A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments.
Beyond The Hustle: Embracing Ancient Chinese Wisdom To Combat Modern Day Burnout
In our modern, high-speed society, many find themselves exhausted in the relentless chase for achievement. Yet, a concept from ancient China that dates back 2,000 years might offer a path to equilibrium and contentment. New York's psychologist, Dr.
From AI to Obesity Drugs – Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments.
This significant financial reserve will be crucial as patents for some of the industry's blockbuster drugs are on the expiration cliff.